Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2008-11-07
2010-11-09
Gussow, Anne M. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S388800, C530S391100, C530S391300, C424S133100, C424S134100, C424S138100, C424S141100, C424S155100, C424S178100
Reexamination Certificate
active
07829678
ABSTRACT:
The present invention provides for recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens, along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to the nucleic acids, and uses for these antibodies, nucleic acids and amino acids.
REFERENCES:
patent: 4810781 (1989-03-01), Hollinshead et al.
patent: 5431897 (1995-07-01), Welt et al.
patent: 5530101 (1996-06-01), Arlen et al.
patent: 5712369 (1998-01-01), Old et al.
patent: 5851526 (1998-12-01), Welt et al.
patent: 6190640 (2001-02-01), Welt et al.
patent: 6291235 (2001-09-01), Welt et al.
patent: 6307026 (2001-10-01), King et al.
patent: 6652853 (2003-11-01), Welt et al.
patent: 7125689 (2006-10-01), Carr et al.
patent: RE39760 (2007-08-01), Tsang et al.
patent: 7314622 (2008-01-01), Arlen et al.
patent: 2003/0031671 (2003-02-01), Welt et al.
patent: 2003/0040027 (2003-02-01), Ritter et al.
patent: 2005/0191617 (2005-09-01), Inoue et al.
patent: 2007/0031327 (2007-02-01), Luzzi et al.
patent: 2009/0041783 (2009-02-01), Takayama et al.
Burgess, Shaheen, Ravera, Jaye, Donohue, and Winkles. Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor 1 from its receptor binding activities by site-directed mutagenesis of a single lysine residue. Journal of Cell Biology, 1990. vol. 111, pp. 2129-2138.
Lazar, Watanabe, Dalton, and Sporn. Transforming growth factor a: mutation of aspartic acid 47 and leucine 48 results in different biological activities. Molecular and Cellular Biology, 1988. vol. 8, pp. 1247-1252.
Rudikoff, Giusti, Cook, and Scharff. Single amino acid substitution altering antigen binding specificity. Proceedings of the National Academy of Sciences, 1982. vol. 79, pp. 1979-1983.
Mac Callum, Martin, and Thornton. Antibody-antigen interactions: contact analysis and binding site topography. Journal of Molecular Biology, 1996. vol. 262, pp. 732-745.
De Pascalis, Iwahashi, Tamura, Padlan, Gonzales, Santos, Giuliano, Schuck, Schlom, and Kashmiri. Grafting of “abbreviated” complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody. Journal of Immunology, 2002. vol. 169, pp. 3076-3084.
Casset, Roux, Mouchet, Bes, Chardes, Granier, Mani, Pugniere, Laune, Pau, Kaczorek, Lahana, and Rees. A peptide mimetic of an anti-CD4 monoclonal antibody by rational design. Biochemical and Biophysical Research Communications, 2003. vol. 307, pp. 198-205.
Vajdos, Adams, Breece, Presta, De Vos, and Sidhu. Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis. Journal of Molecular Biology, 2002. vol. 320, pp. 415-428.
Holm, Jafari, and Sundstrom. Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1. Molecular Immunology, 2007. vol. 44, pp. 1075-1084.
Chen, Weismann, Fuh, Li, Christinger, Mc Kay, De Vos, and Lowman. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. Journal of Molecular Biology, 1999. vol. 293, pp. 865-881.
Wu, Nie, Huse, and Watkins. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues. Journal of Molecular Biology, 1999. vol. 294, pp. 151-162.
International Search Report mailed Aug. 22, 2008.
Heath, J. K. et al., The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily,Proc. Natl. Acad. Sci. USA, 94(2):469-474, 1997.
Hollinshead, A.C. et al., Separation of skin reactive intestinal cancer antigen from the carcinoembryonic antigen of Gold,Science, 177(52):887-889, 1972.
Hollinshead, A. et al., Further comparison's of separated intestinal cancer, fetal intestinal and normal intestinal soluble membrane antigen and the role of tumor related antigens in the diagnosis and treatment of intestinal cancer,Proc. Second Intl. Symp. Cancer Detection and Prevention, Bologna, Italy, pp. 616-620, Apr. 1973.
Hollinshead, A. et al., Skin-reactive soluble antigen from intestinal cancer-cellmembranes and relationship to carcinoembryonic antigens,Lancet, 1(7658):1191-1195, 1970.
Hollinshead, A. et al., Specific active immunotherapy in patients with adenocarcinoma of the colon utilizing tumor-associated antigens (TAA). A phase I clinical trial,Cancer, 56:480-489, 1985.
Johnstone, C. N. et al., Characterization of mouse A33 antigen, a definitive marker for basolateral surfaces of intestinal epithelial cells,Am. J. Physiol. Gastrointest. Liver Physiol., 2000 279(3):G500-G510, 2000.
Kurihara, M. et al., Soluble membrane antigens of gastric cancer cells: an analysis and study of activity in inducing cell-mediated immune responses,J. Jap. Soc. Cancer Ther., 14(3):313-324, 1979.
Ritter, G. et al., Characterization of posttranslational modifications of human A33 antigen, a novel palmitoylated surface glycoprotein of human gastrointestinal epithelium,Biochem. Biophys. Res. Commun., 236(3):682-686, 1997.
Ritter, G. et al., Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33,Cancer Res., 61:6851-6859, 2001.
Welt, S., Phase I study of anticolon cancer humanized antibody A33,Clin. Cancer Res., 9:1338-1346, 2003.
Herlyn et al.; Monoclonal Antibody Detection of a Circulating Tumor-Associated Antigen. 1. Presence of antigen in sera of patients with colorectal, gastric, and pancreatic carcinoma ; J. Clin, Immunol 2(2): pp. 135-140, 1982.
Sears et al.; Monoclonal Antibody Detection of a Circulating Tumor-Associated Antigen. II. A Longitudinal Evaluation of Patients with Colorectal Cancer, Journal of Clinical Immunology, vol. 2, No. 2, 1982.
Bristol J. Andrew
Kantor Judith A.
Gussow Anne M.
Neogenix Oncology, Inc.
Nixon & Peabody LLP
Webster Mary S.
LandOfFree
Recombinant monoclonal antibodies and corresponding antigens... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant monoclonal antibodies and corresponding antigens..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant monoclonal antibodies and corresponding antigens... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4194808